NAB-paclitaxel as third-line therapy after failure of gemcitabine and 5-fluorouracil (5-FU) based combinations in advanced gall bladder cancer patients

被引：0
|
作者：
Goel, V. [1 ]
Talwar, V. [1 ]
Patnaik, N. [2 ]
Raina, S. [1 ]
Singh, S. [1 ]
机构：
[1] Rajiv Gandhi Canc Inst & Res Ctr, Med Oncol, New Delhi, India
[2] UCMS & GTB Hosp, Pathol, Delhi, India
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
241P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical experience with S-1 or FOLFOX as third-line treatment in patients with metastatic pancreatic cancer who received first-line gemcitabine plus nab-paclitaxel and secondline nanoliposomal-irinotecan+5-FU/leucovorin
    Sanomachi, T.
    Ohba, A.
    Ogura, N.
    Hara, H.
    Yagi, S.
    Okada, M. O.
    Maruki, Y.
    Nagashio, Y.
    Kondo, S.
    Susumu, H.
    Morizane, C.
    Ueno, H.
    Okusaka, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S142 - S142
  • [42] VARIATION IN PHARMACOKINETIC DISPOSITION OF 5-FLUOROURACIL (5-FU) IN CANCER-PATIENTS AFTER A SINGLE INTRAVENOUS DOSE
    SITAR, DS
    THIRLWELL, MP
    MANSELL, PW
    RUEDY, JR
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1977, 18 (MAR): : 323 - 323
  • [43] Phase II study of oxaliplatin (OX), 5-fluorouracil (5-FU), and radiation therapy (RT) followed by gemcitabine (GEM) in patients with unresectable pancreatic cancer
    Kim, G. P.
    Haddock, M.
    Foster, N. R.
    Bollinger, J.
    Stella, P. J.
    Kugler, J. W.
    Alberts, S. R.
    Martenson, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Comparison of the Efficacy of Nal-IRI+5FU/LV and S-1 in Patients with Advanced Pancreatic Cancer Refractory to Gemcitabine and Nab-Paclitaxel
    Yamaguchi, Kazuhisa
    Kikuchi, Yoshinori
    Kimura, Yusuke
    Iwasaki, Susumu
    Takuma, Kensuke
    Okano, Naoki
    Matsuda, Takahisa
    ONCOLOGY, 2024,
  • [45] Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer
    Al-Jumayli, Mohammed
    Choucair, Khalil
    Al-Obaidi, Ammar
    Park, Robin
    Bansal, Ajay
    Baranda, Joaquina
    Sun, Weijing
    Saeed, Anwaar
    ANTICANCER RESEARCH, 2022, 42 (01) : 59 - 66
  • [46] Phase I study of docetaxel (TXT) and 5-fluorouracil (5-FU) with concurrent radiotherapy in patients with advanced esophageal cancer
    Hihara, Jun
    Yoshida, Kazuhiro
    Hamai, Yoichi
    Emi, Manabu
    Yamaguchi, Yoshiyuki
    Wadasaki, Koichi
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2597 - 2603
  • [47] Oxaliplatin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in previously treated patients with advanced metastatic gastric cancer
    Cavanna, L
    Zaniboni, A
    Artioli, F
    Lazzaro, A
    Rizzi, A
    Mazzocchi, M
    Anselmi, E
    Bidin, L
    Palladino, M
    Rodinò, C
    ANNALS OF ONCOLOGY, 2005, 16 : 323 - 323
  • [48] Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis
    William H. Isacoff
    Howard A. Reber
    Rudolph Bedford
    William Hoos
    Lola Rahib
    Alexander Upfill-Brown
    Timothy Donahue
    O. Joe Hines
    Targeted Oncology, 2018, 13 : 461 - 468
  • [49] Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis
    Isacoff, William H.
    Reber, Howard A.
    Bedford, Rudolph
    Hoos, William
    Rahib, Lola
    Upfill-Brown, Alexander
    Donahue, Timothy
    Hines, O. Joe
    TARGETED ONCOLOGY, 2018, 13 (04) : 461 - 468
  • [50] Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer
    Roof, Kevin S.
    Coen, John
    Lynch, Thomas J.
    Wright, Cameron
    Fidias, Panos
    Willett, Christopher G.
    Choi, Noah C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (04): : 1120 - 1128
12345